Duane Morris Class Action Review - 2023 - Report - Page 394
1. $7.4 billion – In Re National Prescription Opiate Litigation, Case No. 17-MD02804 (N.D. Ohio Feb. 25, 2022) (settlement agreement reached with distributor
McKesson to resolve the vast majority of the opioid lawsuits filed by state and
local governmental entities).
2. $6.1 billion – In Re National Prescription Opiate Litigation, Case No. 17-MD02804 (N.D. Ohio Feb. 25, 2022) (settlement agreement reached with distributor
AmerisourceBergen to resolve the vast majority of the opioid lawsuits filed by
state and local governmental entities).
3. $6 billion – Sweet, et al. v. Cardona Student Debt Cancellation Settlement,
Case No. 19-CV-03674 (N.D. Cal. Nov. 16, 2022) (final settlement approval
granted for a class action settlement resolving allegations the U.S. Department of
Education failed to address hundreds thousands of applications to a program that
cancels student loan debts for borrowers whose colleges misled them).
4. $6 billion – In Re National Prescription Opiate Litigation, Case No. 17-MD02804 (N.D. Ohio Feb. 25, 2022) (settlement agreement reached with distributor
Cardinal Health to resolve the vast majority of the opioid lawsuits filed by state
and local governmental entities).
5. $5.7 billion – In Re National Prescription Opiate Litigation, Case No. 17-MD02804 (N.D. Ohio Nov. 2, 2022) (settlement agreement reached with retail
pharmacy Walgreens to settle all opioid claims against it by participating states,
subdivisions and tribes).
6. $5.5 billion – In Re National Prescription Opiate Litigation, Case No. 17-MD02804 (N.D. Ohio Mar. 3, 2022) (settlement agreement reached with 13 states
by OxyContin manufacturer Purdue Pharma to resolve claims that the company
held to fuel the U.S. opioid epidemic).
7. $5 billion – In Re National Prescription Opiate Litigation, Case No. 17-MD02804 (N.D. Ohio Feb. 25, 2022) (settlement agreement reached with Johnson
& Johnson, the consumer products and health company that manufactured
generic opioid medications, to resolve the vast majority of the opioid lawsuits filed
by state and local governmental entities).
8. $5 billion – In Re National Prescription Opiate Litigation, Case No. 17-MD02804 (N.D. Ohio Nov. 2, 2022) (settlement agreement reached with CVS
Pharmacy to settle all opioid claims against it by participating states, subdivisions
and tribes).
9. $4.25 billion – In Re National Prescription Opiate Litigation, Case No. 17MD-02804 (N.D. Ohio Nov. 22, 2022) (settlement agreement reached with Teva
Pharmaceutical Industries to resolve thousands of lawsuits by U.S. state and
local governments over the marketing of opioid painkillers).
393
© Duane Morris LLP 2023
Duane Morris Class Action Review – 2023
